I. Municipal Level
(I) Development Positioning, Layout and Goals
1. Development Positioning
The pharmaceutical and healthcare industry is one of the top ten high-end, precision and sophisticated industries in Beijing and one of the two internationally leading pillar industries under privileged cultivation and development in Beijing.
2. Development Layout
The pharmaceutical and healthcare industry in Beijing has two bases, one in the south, represented by Daxing and Yizhuang with a focus on achievement transformation and the other in the north, represented by Haidian and Changping with a focus on technological innovation and R&D.
3. Development Goals
(1) Beijing will aim at three major directions of innovative drugs, new devices, and new healthcare services, and build leading advantages in new vaccines, next generation of antibody drugs, cell and gene therapy, and domestic high-end medical devices for the parallel development of pharmaceutical manufacturing and healthcare services.
Source: For more details, see the Plan of Beijing Municipality for the Development of High-end, Precision and Sophisticated Industries during the 14th Five-Year Plan.
(2) Beijing will continue to promote the sustained development of innovative drugs, accelerate the technological innovation in the medical device industry, support the R&D of globally patented innovative drugs with new targets, mechanisms, structures, and technologies, give priority to industrial development of medical robots, high-end implantable consumables and other characteristic medical devices, and add 12 new varieties of innovative drugs and 30 innovative medical devices. The Municipality will also boost technological innovations such as recombinant vaccines, multivalent combined vaccines, and new adjuvants and realize their industrial application in Beijing. Efforts will also be made to build a vaccine production system with all elements and full chains to meet the requirements of different technical routes and foster a vaccine industrial cluster up to international standards.
(3) Beijing will promote the development of the beauty and healthcare industry, build an international information platform for cosmetics, and lead internationally renowned brands to set up R&D and sales headquarters and production bases in Beijing. The Municipality will also underpin the development of Beijing Institute for Innovation in Healthcare Industry and Demonstration Base for Innovation in Beauty and Health Industry in Beijing.
(4) Beijing will dig deeper for classic and famous prescriptions in the city, explore the norms on prescription use and management among medical institutions in Beijing, encourage, support and expedite the transformation of classic and famous prescriptions and medical institutional preparations into new drugs for industrial application.
Source: For more details of items (2)-(4), see the Plan of Beijing for Drug Safety and High-quality Development during the 14th Five-Year Plan Period.
(II) Support Policies
1. When eligible enterprises above the designated size in biomedical production and R&D in Beijing Apply for recognition as high-tech enterprises, they may immediately enjoy preferential income tax and other relevant policies in accordance with regulations on the basis of “approval upon filing”.
Source: For more details, see the Implementation Plan of Beijing Municipality for the Pilot Policy of Approval upon Filing in Recognition of High-tech Enterprises.
Contact: Beijing Municipal Science & Technology Commission, Administrative Commission of Zhongguancun Science Park
Tel: 010-55577777
2. Pharmaceutical enterprises are encouraged to actively engage in international product certification. An incentive of RMB 2 million for a drug or high-end medical device registered through FDA, EMA, PMDA, WHO and other international agencies within the recent two years, produced in Beijing and sold in corresponding foreign markets. The incentive is not more than RMB 10 million for each enterprise every year.
Source: For more details, see the Several Measures of Beijing Municipality to Promote High-quality Development of Specialized and Sophisticated Small and Medium-sized Enterprises That Produce New and Unique Products.
Contact: Beijing Municipal Bureau of Economy and Information Technology
Tel: 010-55578300
3. Incentives will be provided for the first pilot production of innovative pharmaceutical products. Class I/II drugs and COVID-19 therapeutics that have entered phase II clinical trials and beyond, have been under special/priority review procedures for innovative medical devices entering Beijing and other cities in China or have been registered with emergency approval in Beijing/included in the list of medical devices by the Ministry of Industry and Information Technology under the open competition mechanism to select the best candidates since 2022 and are determined to be industrially applied in Beijing will be provided with incentives of not more than RMB 5 million for each drug and RMB 2 million for each medical device.
4. An incentive of not more than RMB 2 million will be granted to the newly registered drugs in Beijing that have been among the first batch of generic drugs since 2022, the first three generic drugs that have passed the consistency evaluation on the quality and efficacy, and the newly listed ones in the Catalogue of Encouraged Generic Drugs, National List of Drugs in Shortage and National List of Drugs on Key Monitoring for Clinical Necessity and Vulnerability to Shortage.
5. An incentive of not more than RMB 2 million to domestically registered and listed innovative drugs and Class III medical devices registered through FDA, EMA, PMDA, WHO and other authoritative international institutions since 2022 and sold in corresponding foreign markets.
Source: For more details, see the Guidelines of Beijing Municipality for the Implementation of Development Fund for High-end, Precision and Sophisticated Industries (First Batch).
Contact: Beijing Municipal Bureau of Economy and Information Technology
Tel: 010-55578183
6. Support will be granted for major technological innovations in pharmaceuticals and medical devices. A financial subsidy of not more than 30% of the total project investment, up to RMB 10 million every year, will be granted to selected outstanding enterprises with innovative drugs that have completed phase II clinical trial or first batch of generic drugs in China that have passed the consistency evaluation on the quality and efficacy, equipped with independent intellectual property rights and Class II/III medical device registration certificates and production licenses applied for and obtained in Beijing.
7. Enterprises are encouraged to purchase supporting devices through financial leasing and will be subsidized by 20% of financing expenses, up to RMB 500,000 for not more than 3 years on the same business.
8. Support will be granted for the development of professional platforms for pharmaceutical and medical devices as well as testing and inspection services, and centers for medical achievement transformation in Zhongguancun. Financial support of not more than 30% of the total project investment and up to RMB 10 million every year will be granted.
9. Support will be granted to pharmaceutical and medical device enterprises to expand their market. The enterprises will receive subsidies equivalent to 80% of the insurance premiums for clinical trials and comprehensive liabilities, up to RMB 1 million for each enterprise every year.
10. Support will be granted to pharmaceutical and medical device enterprises for restructuring, listing and mergers and acquisitions. A financial support of RMB 100,000 will be granted to each restructured enterprise, RMB 50,000 will be granted to each enterprise listed on the standard board and the science and technology innovation board at Beijing Equity Trading Center, and RMB 300,000, to each enterprise approved to be listed on NEEQ. In support of mergers and acquisitions of pharmaceutical and medical device enterprises, financial support equivalent to 5‰ of the transaction volume will be granted for a transaction with a total volume of RMB 10 million or more. The support will not be more than RMB5 00,000 for each project every year, and not more than RMB 1 million for each enterprise every year.
11. Capacity building will be enhanced for professional incubation of pharmaceuticals and medical devices. Incubators will be granted subsidies not more than 30% of their actual investment, up to RMB 3 million every year. The incubators with outstanding service performance will be selected to be supported as a Zhongguancun Hard Technology Incubator, with a financial fund of not more than 30% of the total investment in the incubator, up to RMB 10 million every year.
12. Support will be granted for the development of service institutions for commercialization of scientific and technological achievements in the pharmaceutical and healthcare industry. The institutions with outstanding service performance will be granted financial support of not more than 50% of the actual expenses incurred based on performance and evaluation results, up to RMB 2 million every year.
13. Support will be granted to characteristic parks for improvement of their operational service capabilities. Park constructors and operator are encouraged to provide professional services for settled enterprises, hold influential and characteristic field activities, and increase supporting service facilities. Institutions carrying out the above-mentioned work will be granted financial support of not more than 30% of the actual investment, up to RMB 2 million every year for characteristic parks in downtown city and RMB 3 million every year for those not in downtown city.
14. Support will be granted for the organization of related entrepreneurial activities and subsidies not more than 30% of the actual expenditure of the organized activities will be granted. The subsidies will be up to RMB 1 million every year for each organizer.
15. Risk subsidies will be granted to eligible angel investment institutions by 15% of their actual investment, up to RMB 500,000 of each subsidy and RMB1.5 million in total for each investment institution every year. The subsidies for eligible start-up investment institutions will be 10% of their actual investment, up to RMB 1 million of each subsidy and RMB 2 million in total for each investment institution every year.
16. Support will be granted to global leading pharmaceutical and medical device enterprises for building regional headquarters and R&D centers in the Zhongguancun Demonstration Zone. The financial support will be 30% of the actual expenses incurred in house purchase, lease, and R&D device purchase, up to RMB 5 million for each enterprise every year.
17. Support will be granted to enterprises in Zhongguancun Demonstration Zone for setting up international R&D institutions. For pharmaceutical and medical device enterprises establishing branches such as R&D centers overseas, one-time support not more than 30% of the actual expenses incurred for the establishment will be granted. The support will be up to RMB600,000 for each branch.
18. Enterprises in Zhongguancun Demonstration Zone are encouraged to jointly carry out R&D cooperation with top overseas universities and institutes and global leading innovative peers. One-time financial subsidy of not more than 30% of the R&D expenses in each project and up to RMB 1 million will be granted. The support will be not more than RMB 3 million cumulatively for each enterprise every year.
Source: For more details of items 6-18, see the Several Measures for Promoting the Innovative Development of the Pharmaceutical and Medical Device Industry in Zhongguancun National Innovation Demonstration Zone.
Contact: Beijing Municipal Science & Technology Commission, Administrative Commission of Zhongguancun Science Park
Tel: 010-88827155
II. District Level
(I) Haidian District
1. Key Projects
Global R&D centers for drugs in healthcare, innovation centers for medical robots, “BioFront” new drug discovery platform, “Nest.Bio” labs, and “Quaerite” preparation platform.
2. Key Areas
New drug R&D, high-end medical devices, and intelligent healthcare
3. Support Policies
Directions:
Pharmaceutical field, mainly including antibody drugs, vaccines, recombinant protein and peptide drugs, gene therapy, immune cell therapy represented by CAR-T, stem cell therapy, nucleic acid drugs and other innovative drugs and high-end biological products, innovative chemical drugs and high-end preparations, and modern Chinese medicines.
Medical device field, mainly including high-end medical imaging devices, implantable interventional devices and high-value consumables, medical robots, advanced treatment devices and life support devices, high-end rehabilitation aids and devices, in vitro diagnostic devices and reagents, organ chips, brain-computer intelligence, AI medical software, digital medical products and biomedical materials.
Details:
(1) Early R&D, clinical trials, and industrial commercialization of innovative varieties are encouraged. Excellent R&D and industrialization projects of innovative drugs and medical devices will be selected and subsidized based on different phases by not more than 30% of the R&D investment, up to RMB 3 million. The subsidy will be not more than RMB 10 million for each enterprise every year and not more than RMB 10 million for each variety in total.
(2) Enterprises are encouraged to realize R&D value in various ways. Enterprises that have fostered major original varieties and generated income and taxes through the transfer of patents, clinical approval documents and other early achievements, including transfer income, milestone income, and future drug market share, with a transfer income of no less than RMB 500 million, will be eligible for an incentive of up to RMB 2 million for each variety. The incentive will be not more than RMB 10 million for each enterprise every year.
(3) To promote the development of a third-party professional public service platform for pharmaceutical and healthcare and support the provision of professional services on public service platforms for pharmaceutical and health, support will be granted to particularly important platform projects on a case-by-case basis or with high-growth fund equity investment as enterprises wish.
Source: For more details of items (1)-(3, see the 2022 Guidelines of Haidian District for Special Project Application in the Development of the Pharmaceutical and Healthcare Industry. (Note: the 2022 policy is for reference only, subject to the latest notice in the subsequent years.)
Contact: Administrative Commission of Zhongguancun Science City
Tel: 010-88498950
(II) Changping District
In the future, Zhongguancun Life Science Park can provide about 1.67 million square meters of industrial space, 1.5 million square meters of residential space, and 280,000 square meters of supporting facilities.
1. Key Projects
R&D institutions: National Institute of Biological Sciences, Beijing, Chinese Institute for Brain Research, Beijing, National Center for Protein Science, and R&D Center of Seragon Pharmaceuticals
Service platforms: Beijing Center for Vaccine Control, China’s first international research-based hospital dedicated to the transformation of clinical research, Bio2, ATLATL, and other international professional platforms
Representative enterprises: Novartis, Lepu, Wantai BioPharm, BeiGene, etc.
2. Key Areas
Cutting-edge technology, medical devices, beauty and healthcare
3. Support Policies
Directions:
R&D innovation and industrial application of innovative drugs, high-end medical devices, cell and gene therapy, AI+ pharmaceuticals and precision medical services as well as the development and operation of public service platforms for the pharmaceutical and healthcare industry and professional services such as CRO, CDMO, CMO, and CSO.
Details:
(1) For the development of regional headquarters and R&D centers by global leading enterprises in pharmaceuticals and medical equipment, a rent subsidy of up to RMB 5 million will be provided.
(2) To introduce advanced technology for industrial application in the District, an incentive of not more than RMB 1 million for each product and not more than RMB 10 million for each enterprise will be granted after the launch of the product.
(3) An incentive of up to RMB 2 million will be granted for Class I biomedical products, chemical drugs and Chinese medicines entering clinical trials and an incentive of up to RMB 500,000 for each product and RMB 1 million for each enterprise will be granted for those with non-registered clinical trials in frontier fields.
(4) Those with newly obtained drug registration certificate that produce or settle Class I biomedical products, chemical drugs and Chinese medicines in the District will be eligible for an incentive of RMB 2 million for each product and not more than RMB 10 million for each enterprise.
(5) For products registered in and certified by international authoritative organizations and produced or settled in the District, a subsidy of up to RMB 1 million will be granted for each kind of drug. The subsidy will be up to RMB 3 million for each enterprise every year. For medical devices meeting the above criteria, subsidies of up to RMB 500,000 will be provided for each product. The subsidies will be not more than RMB 1.5 million for each enterprise every year.
(6) The acquisition of new drug/equipment production approval documents will be supported by up to RMB 10 million.
(7) Fixed asset investment will be subsidized by up to RMB 50 million for each enterprise.
(8) Enterprises with pharmaceutical and medical equipment produced or settled in the District will be eligible for an incentive of up to RMB 10 million based on annual output value or sales revenue. For medical service providers, an incentive of up to RMB 4 million will be provided based on main operating revenue.
(9) To increase R&D investment of settled enterprises, those with a total R&D investment of more than RMB 10 million over the previous two declaration years and an operating revenue of less than RMB 20 million in the previous year will be eligible for a subsidy equivalent to 10% of their R&D investment in the previous year, up to RMB 500,000 for each enterprise every year, and for not more than three cumulative years.
(10) Pharmaceutical and healthcare enterprises that have passed the evaluation and recognition will be preferably recommended to enjoy preferential policy treatment in municipal and district talent services, housing security, headquarters enterprises, listing incentives, scenario applications and government procurement.
Source: For more details of items (1)-(10), see the Interim Measures to Jointly Support the Development of the Pharmaceutical and Healthcare Industry in Changping and Sci-Technology Innovation Area, a Subzone of China (Beijing) Pilot Free Trade Zone.
Contact: Changping District Investment Promotion Service Center
Tel: 010-69726240
(III) Economic-Technological Development Area
1. Key Projects
A public service platform for biotechnology and a pilot base for cell therapy R&D.
2. Key Areas
Biotechnology, high-end medical devices, and pharmaceutical and healthcare services.
3. Support Policies
Details:
(1) Financial support of up to RMB 20 million will be granted to enterprises that undertake national and municipal scientific and technological plans and projects in small molecule original drugs, new antibody drugs, new vaccines, cell therapy, innovative preparation, gene diagnosis and treatment, high-end medical devices, and modern Chinese medicines and initiate Phase I, II, or III clinical trials in their projects.
(2) Enterprises in the Area that undertake high-quality project transformation and have innovative products transformed, applied and approved for production will be granted financial support up to RMB 50 million for each product.
(3) Certain financial support will be granted to recognized medical service platforms selected on the basis of merits.
(4) The transformation of cross-industry technological achievements will be promoted. Efforts will be made to strengthen the development of mechanisms for key technology integration and boost the transformation of cross-field medical achievements.
(5) Financial support will be provided for international multi-center clinical research on biomedical products and a green channel for import and export will be built for the products.
(6) Innovative technologies and teams will be supported to settle in the Area under the one-enterprise-one-policy mechanism.
(7) The supply of biomedical space will be strengthened, with support given to the development of customized workshops to achieve space supply covering all stages.
(8) Healthcare institutions are encouraged to build research-based hospitals and promote the development of emerging service business formats.
Source: For more details of items (1)-(8), see the Implementation Opinions of Beijing Economic-Technological Development Area on Accelerating the Development of Four Leading Industries.
Contact: Administrative Commission of Beijing Economic-Technological Development Area
Tel: 010-67881316
(IV) Daxing District
Daxing Biomedical Industry Base, the largest biomedical industry base in Beijing, is a national park dedicated to the pharmaceutical and healthcare industry. Aiming for the “China Bio-medicine Park” (CBP), it will become China’s largest park dedicated to the pharmaceutical and healthcare industry with a total coverage of 22.5 square kilometers. It will feature an industrial pattern of “1+4+2”, dominated by R&D and inspection sectors, with biopharmaceuticals, modern Chinese medicines, innovative chemical drugs, and medical devices as main segments and One Health and animal medicine as expanded segments in the gradual development of a new healthy city that integrates research, production, business, exhibition and therapy.
1. Key Projects
ZGC Medical Device Park, Tongrentang Major Modern Industrial Parks, and CBP Innovation Center.
Service Platforms: National Institutes for Food and Drug Control
Representative enterprises: Beijing Tongrentang, Beijing Sinovac Life Sciences and Beijing Hotgen Biotech
2. Key Areas
Biopharmaceuticals, innovative drugs, modern Chinese medicines, high-end medical devices, healthcare services and other industries.
Biopharmaceuticals: subdivided fields such as gene diagnosis and treatment, new vaccines, antibodies, and cellular immunotherapy.
Innovative drugs: R&D of new drugs such as tumor-targeted small molecule drugs and drugs for the treatment of rare diseases.
Modern Chinese medicines: major varieties of characteristic Chinese medicinal materials.
High-end medical devices: in vitro diagnostics, nursing and rehabilitation devices, etc.
3. Support Policies
(1) Subsidies will be provided for enterprises or projects that are expected to make major breakthroughs in the pharmaceutical and healthcare industry, team up leading international talents, introduce internationally leading technologies and varieties, and obtain a certain scale of investment. The subsidies will be equivalent to 30% of the total actual investment in project fixed assets (excluding real estate, land and personnel) and provided at different stages, up to RMB 300 million for each project.
(2) Subsidies will be granted to enterprises that lease functional premises with legal formats as office, R&D centers and production sites. The subsidies will be equivalent to 50% of the previous year’s actual rent paid, up to 50% of the guiding rent price in the surrounding area for not more than three years, up to RMB 5 million every year.
(3) Enterprises with Class I chemical drugs, biomedical products and Chinese medicines will be supported by up to RMB 10 million, 20 million and 40 million based on phase I, Phase II and Phase III of clinical trials respectively, up to RMB 100 million for each enterprise every year.
(4) Enterprises with Class II chemical drugs, bio-products (excluding in vitro diagnostic reagents) and Chinese medicines will be supported by up to RMB 3 million, 8 million and 18 million based on phase I, Phase II and Phase III of clinical trials respectively, up to RMB 30 million for each enterprise every year.
(5) One-time financial support of RMB 10 million, 5 million and 3 million will be granted to projects that have obtained drug registration approval documents within three years and implemented industrial application, for each approval document of the national Class I new drug, national Class II new drug and other type respectively, up to RMB 20 million for a single enterprise every year.
(6) One-time financial support will be given to projects with Class III medical equipment products that have obtained the medical equipment registration certificate within three years and implemented industrial application. The support will be RMB 2 million for each product and up to RMB 5 million for each enterprise every year.
(7) Financial support will be given to drug marketing authorization holders or medical equipment registrants who entrust biopharmaceutical enterprises to produce the products they hold. The support will be equivalent to 10% of the actual transaction amount of the product of each kind, up to RMB 5 million and not more than RMB 20 million for each enterprise every year.
(8) Financial support will be granted to biopharmaceutical enterprises that undertake production in accordance with the drug marketing authorization holder system and medical equipment registrant system. The support will be 10% of the actual investment, up to RMB 15 million for each kind of product and no more than RMB 30 million for each enterprise every year.
(9) Pharmaceutical enterprises with a main operating revenue of RMB 500 million or more in the previous year will be eligible for financial support equivalent to 2‰ of the main operating revenue, up to RMB 100 million. Those with a main operating revenue of RMB 500 million or more and a positive growth in the previous year will be granted financial support equivalent to 3‰ of the increase in main operating revenue in the previous year.
(10) Enterprises that have received national and municipal special funds in the previous year will be granted corresponding financial support in proportion of 100% and 50% of the special funds, up to RMB 10 million and RMB 5 million, respectively.
(11) A special fund for the transformation of scientific and technological achievements will be set up, mainly for the investment in pharmaceutical and healthcare industries. The fund will hole shares up to 30% of the total share capital of the invested project or enterprise. It will mainly introduce and support R&D in biomedical innovation projects, biomedical start-up enterprises, high-growth enterprises and key projects.
(12) Support will be granted for the development of contract research organizations (CROs), contract manufacture organizations (CMOs), and contract development and manufacturing organizations (CDMOs). Financial support equivalent to 20% of annual actual service fees and up to RMB 10 million will be offered to platforms that provide professional technologies and public services such as drug screening, drug synthesis, pharmacology and toxicology research, effectiveness evaluation, experimental animal services, registration and application of clinical research on new drugs, post-marketing clinical research, pharmaceutical industrial waste treatment and pharmaceutical intellectual property transactions, after review and recognition. The support will be provided for not more than three years.
(13) Support will be granted for the development of research centers for clinical medicine. Enterprises, universities, and relevant institutions will be encouraged to collaboratively build research centers for clinical medicine, conduct international multi-center clinical trials, build clinical sample resource banks, health big data platforms, and clinical evaluation platforms for drugs and medical devices. The projects will be supported with an amount equivalent to 50% of the actual total investment of the project (excluding real estate, land and personnel), up to RMB 30 million.
Source: For more details, see the Several Measures of Daxing District to Promote the Development of the Pharmaceutical and Healthcare Industry (Revised in 2022).
Contact: Daxing District Science and Technology Committee
Tel: 010-69252567
Note: If a single entity is eligible for multiple support policies, the most favorable policy shall apply. The responsibility to interpret each specific policy shall be borne by the issuing agency.